Home/Filings/4/0000950170-24-007348
4//SEC Filing

Lynch Brian Joseph 4

Accession 0000950170-24-007348

CIK 0001157601other

Filed

Jan 24, 7:00 PM ET

Accepted

Jan 25, 3:24 PM ET

Size

10.4 KB

Accession

0000950170-24-007348

Insider Transaction Report

Form 4
Period: 2024-01-23
Lynch Brian Joseph
SVP and General Counsel
Transactions
  • Award

    Market Stock Unit

    2024-01-23+3,6393,639 total
    Common Stock (3,639 underlying)
  • Award

    Common Stock

    2024-01-23+3,63917,691 total
  • Award

    Stock Option (Right to Buy)

    2024-01-23+5,4835,483 total
    Exercise: $229.00Exp: 2031-01-23Common Stock (5,483 underlying)
Holdings
  • Common Stock

    (indirect: By IRA)
    530
Footnotes (3)
  • [F1]Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
  • [F2]The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
  • [F3]Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

Documents

1 file

Issuer

MADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

Entity typeother

Related Parties

1
  • filerCIK 0001776196

Filing Metadata

Form type
4
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 3:24 PM ET
Size
10.4 KB